Detalhe da pesquisa
1.
A phase 2 trial exploring the significance of homologous recombination status in patients with platinum sensitive or platinum resistant relapsed ovarian cancer receiving combination cediranib and olaparib.
Gynecol Oncol
; 187: 105-112, 2024 May 16.
Artigo
em Inglês
| MEDLINE | ID: mdl-38759516
2.
Uterine MEIS1::NCOA2 Fusion Sarcoma With Lung Metastasis: A Case Report and Review of the Literature.
Int J Gynecol Pathol
; 43(1): 47-55, 2024 Jan 01.
Artigo
em Inglês
| MEDLINE | ID: mdl-37043646
3.
Randomized phase II trial of farletuzumab plus chemotherapy versus placebo plus chemotherapy in low CA-125 platinum-sensitive ovarian cancer.
Gynecol Oncol
; 170: 300-308, 2023 03.
Artigo
em Inglês
| MEDLINE | ID: mdl-36758420
4.
Secondary Surgical Cytoreduction for Recurrent Ovarian Cancer.
N Engl J Med
; 381(20): 1929-1939, 2019 11 14.
Artigo
em Inglês
| MEDLINE | ID: mdl-31722153
5.
What proportion of patients with stage 3 ovarian cancer are potentially cured following intraperitoneal chemotherapy? Analysis of the long term (≥10 years) survivors in NRG/GOG randomized clinical trials of intraperitoneal and intravenous chemotherapy in stage III ovarian cancer.
Gynecol Oncol
; 166(3): 410-416, 2022 09.
Artigo
em Inglês
| MEDLINE | ID: mdl-35835612
6.
NCCN Guidelines® Insights: Ovarian Cancer, Version 3.2022.
J Natl Compr Canc Netw
; 20(9): 972-980, 2022 09.
Artigo
em Inglês
| MEDLINE | ID: mdl-36075393
7.
Post hoc analyses of GOG 9923: Does BRCA status affect toxicities?: An NRG oncology study.
Gynecol Oncol
; 161(2): 512-515, 2021 05.
Artigo
em Inglês
| MEDLINE | ID: mdl-33610319
8.
Combination ATR and PARP Inhibitor (CAPRI): A phase 2 study of ceralasertib plus olaparib in patients with recurrent, platinum-resistant epithelial ovarian cancer.
Gynecol Oncol
; 163(2): 246-253, 2021 11.
Artigo
em Inglês
| MEDLINE | ID: mdl-34620496
9.
Ovarian Cancer, Version 2.2020, NCCN Clinical Practice Guidelines in Oncology.
J Natl Compr Canc Netw
; 19(2): 191-226, 2021 02 02.
Artigo
em Inglês
| MEDLINE | ID: mdl-33545690
10.
Rucaparib maintenance treatment for recurrent ovarian carcinoma: the effects of progression-free interval and prior therapies on efficacy and safety in the randomized phase III trial ARIEL3.
Int J Gynecol Cancer
; 31(7): 949-958, 2021 07.
Artigo
em Inglês
| MEDLINE | ID: mdl-34103386
11.
Rucaparib for patients with platinum-sensitive, recurrent ovarian carcinoma (ARIEL3): post-progression outcomes and updated safety results from a randomised, placebo-controlled, phase 3 trial.
Lancet Oncol
; 21(5): 710-722, 2020 05.
Artigo
em Inglês
| MEDLINE | ID: mdl-32359490
12.
Frontline PARP inhibitor maintenance therapy in ovarian cancer: A Society of Gynecologic Oncology practice statement.
Gynecol Oncol
; 159(1): 8-12, 2020 10.
Artigo
em Inglês
| MEDLINE | ID: mdl-32778410
13.
Anti-cancer therapy and clinical trial considerations for gynecologic oncology patients during the COVID-19 pandemic crisis.
Gynecol Oncol
; 158(1): 16-24, 2020 07.
Artigo
em Inglês
| MEDLINE | ID: mdl-32386911
14.
A phase I study of intravenous or intraperitoneal platinum based chemotherapy in combination with veliparib and bevacizumab in newly diagnosed ovarian, primary peritoneal and fallopian tube cancer.
Gynecol Oncol
; 156(1): 13-22, 2020 01.
Artigo
em Inglês
| MEDLINE | ID: mdl-31708167
15.
The effect of age on efficacy, safety and patient-centered outcomes with rucaparib: A post hoc exploratory analysis of ARIEL3, a phase 3, randomized, maintenance study in patients with recurrent ovarian carcinoma.
Gynecol Oncol
; 159(1): 101-111, 2020 10.
Artigo
em Inglês
| MEDLINE | ID: mdl-32861537
16.
The estrogen receptor-alpha S118P variant does not affect breast cancer incidence or response to endocrine therapies.
Breast Cancer Res Treat
; 174(2): 401-412, 2019 Apr.
Artigo
em Inglês
| MEDLINE | ID: mdl-30560461
17.
Differences in presentation and survival of Asians compared to Caucasians with ovarian cancer: An NRG Oncology/GOG Ancillary study of 7914 patients.
Gynecol Oncol
; 154(2): 420-425, 2019 08.
Artigo
em Inglês
| MEDLINE | ID: mdl-31229298
18.
NCCN Guidelines Insights: Ovarian Cancer, Version 1.2019.
J Natl Compr Canc Netw
; 17(8): 896-909, 2019 08 01.
Artigo
em Inglês
| MEDLINE | ID: mdl-31390583
19.
Introduction: the 12th Biennial Rivkin Center Ovarian Cancer Research Symposium.
Int J Gynecol Cancer
; 29(Suppl 2): s1, 2019 08.
Artigo
em Inglês
| MEDLINE | ID: mdl-31462540
20.
Anticipated stigma and healthcare utilization in COPD and neurological disorders.
Appl Nurs Res
; 45: 63-68, 2019 02.
Artigo
em Inglês
| MEDLINE | ID: mdl-30683254